Related Experiment Video
Updated: May 23, 2026
07:56
Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Bone mass pharmacogenetics and ethnic health implications
Francesco Massart1, Maria Luisa Brandi
1Pediatric Department, University of Pisa, Pisa, Italy.
Summary
Osteoporosis risk is influenced by genetics, affecting bone mineral density and fracture susceptibility. Gene variations, like in vitamin D and estrogen receptors, may explain ethnic differences in treatment response.
Area of Science:
- Genetics and Bone Biology
- Pharmacogenomics
- Skeletal Health
Background:
- Osteoporosis is a prevalent skeletal disease with significant genetic underpinnings, increasing fracture risk.
- Bone mineral density (BMD) is a key predictor of osteoporotic fractures.
- Genetic factors influence bone quality, but specific genes remain debated.
Purpose of the Study:
- To explore the role of genetic variability in osteoporosis.
- To investigate how gene polymorphisms, specifically in vitamin D receptor (VDR) and estrogen receptor alpha (ERα), influence treatment response.
- To understand ethnic variations in osteoporosis morbidity and treatment efficacy.
Main Methods:
- Review of studies examining gene variability and BMD.
- Analysis of VDR and ERα polymorphisms in relation to hormonal treatment response.
- Consideration of ethnic differences in gene allele frequencies.
Main Results:
- Genetic factors substantially impact bone quality and BMD.
- Polymorphisms in VDR and ERα are potential determinants of response to vitamin D and estrogen therapies.
- Ethnic variations in VDR and ERα gene distribution may explain differences in osteoporosis treatment outcomes.
Conclusions:
- Understanding gene polymorphisms is crucial for personalized osteoporosis management.
- Genetic factors, particularly VDR and ERα variations, play a role in ethnic differences in osteoporosis treatment efficacy.
- Future osteoporosis strategies must incorporate genetic insights for effective prevention and treatment.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...